Dear Editor,

The novel coronavirus disease (COVID-19) has impacted almost every healthcare system worldwide. Due to the priority of containing the spread, elective surgeries were largely suspended in many affected areas. Urology has been one of the most impacted surgical specialties with significant clinical implications. As states across the United States (US) have begun to undergo phased re-opening, healthcare systems are having to adapt on the evolving situations and safely resume elective surgeries. Our institution has implemented universal screening for patients whose procedures delaying greater than 30 days may negatively impact outcomes. Herein, we report the feasibility and safety of a system-wide approach using SARS-COV-2 microbiologic testing to ensure a safe return of elective procedures that can be used as reference for other centers aiming to increase surgical capacity.

Between May 1st and May 31st, 2020, a total of 153 cases were performed at Banner-University Medical Center facilities in Tucson, Arizona, US. Institutional IRB was obtained (protocol number 2006792802). All patients were screened for COVID-19 symptoms by a dedicated anesthesia nurse by phone for symptoms. Additionally, a history of diabetes, COPD, CAD, and use of immunosuppressants were recorded for risk stratification. All patients underwent nasopharyngeal swab for SARS-CoV-2 polymerase-chain reaction (PCR) as well IgM and IgG antibody tests within 7 days of the scheduled surgery. Those whose PCR test returned negative were asked to self-isolate until the day of surgery. Patients with positive antibody and negative PCR test were asked to obtain a repeat negative PCR test prior to proceeding with surgery. If the PCR test was positive, patients were asked to self-quarantine as per CDC guidelines \[[@CR1]\]. Because false-negatives may occur with testing, droplet precautions were used by peri-operative staff on all cases.

Of the 153 patients who underwent surgeries, the median age was 63 (range 13--85) and 58% were male (Table [1](#Tab1){ref-type="table"}). 63 (41.2%) have risk factors for immune dysfunction. One patient was diagnosed with COVID-19 by PCR test. He resided in a skilled nursing facility and was later tested as IgG positive but negative PCR test. He was then allowed to proceed with surgery. We had one patient who developed symptoms 9 days after surgery with positive PCR test. He subsequently required intubation in intensive care unit. None of the care team members were diagnosed with COVID-19 at the end of this study period.Table 1Patient risk factors and perioperative SARS-CoV-2 diagnostic testing resultAge (median, range)DM (*n*, %)COPD (*n*, %)CAD (*n*, %)Immuno-suppressant use (*n*, %)Surgery type (*n*, %)COVID-19 test (*n*, %)COVID-19 (+) after surgery63 (13--85)35 (22.9%)11 (7.2%)12 (7.8%)5 (3.3%)Oncologic(27, 17.6%)Reconstructive(21, 13.7%)Endoscopic(86, 56.2%)Others(19, 12.4%)IgG (+)(1, 0.7%)RNA (+)(0)1 (0.7%)*DM* diabetes mellitus, *COPD* chronic obstructive pulmonary disease, *CAD* coronary artery disease

As SARS-CoV-2 may spread in asymptomatic patients, universal testing for all incoming surgical patients is required \[[@CR2]\]. We believe a safe return of elective surgeries has three main requirements to fulfil: (1) the risk to contract COVID-19 during the operation and hospitalization should be minimal or at least no greater than those outside of hospital; (2) the healthcare workers should be equipped and protected should any positive cases occur; and (3) the hospital must have adequate resources dedicated to the care of COVID-19 patients. As seen in our high-risk cohort of urology patients, our outlined approach has demonstrated initial feasibility for the safe return of elective surgical procedures.
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